Indication: For treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease
Pharmacology: Chlorambucil is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.
Mechanism Of Action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
Interactions:
DrugBank: Interactions for Chlorambucil
Interactions for Chlorambucil:
There are no known drug/drug interactions with chlorambucil.
Chemical IUPAC Name: 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoicacid
Chemical Formula: C14H19Cl2NO2
Half Life: 1.5 hours
Drug Type: Approved Drug
# Accession No: APRD00115
CAS Registry Number: 305-03-3
Chlorambucil News (When available)
Potential Pathogenetic Implications of Cyclooxygenase-2 ...Dec 7, 2005 Am J Pathology (subscription) ...lymphocytes. Pretreatment with NS-398 significantly potentiated the cytotoxicity induced by chlorambucil in 8 of 16 B-CLL samples examined. ...
From a cause, a cureJan 8, 2006 Boston Globe, ...first performed at Yale in the mid-1940s, on a patient with Hodgkin's disease, which regressed dramatically after treatment with nitrogen mustard, a related ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
